World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
35492
World Ranking
9620
National Ranking
4958

Raymond Alexanian publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Raymond Alexanian sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 271 publications — 11th percentile

11% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Raymond Alexanian D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Raymond Alexanian sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 96 D-Index — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Raymond Alexanian is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans several fields of study, with a primary focus on Medicine, supported by contributions in Biochemistry, Genetics, and Molecular Biology.

The scientist's work addresses important subfields including Hematology, Molecular Biology, Genetics, and Oncology. Their investigations notably cover topics such as Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Myeloproliferative Neoplasms: Diagnosis and Treatment, and Peptidase Inhibition and Analysis.

Their recent scholarly output includes publications in venues such as Blood Cancer Journal and UNC Libraries. Notable papers authored or co-authored by them are:

  • Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up, 2021, Blood Cancer Journal
  • A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma, 2021, UNC Libraries

Raymond Alexanian has collaborated frequently with other researchers in their field. Frequent co-authors include:

  • Robert Z. Orlowski
  • Elisabet E. Manasanch
  • Chutima Kunacheewa
  • Catherine M. Claussen
  • Hans C. Lee

Best Publications

  • A phase 2 study of bortezomib in relapsed, refractory myeloma.

    Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal

  • International uniform response criteria for multiple myeloma

    B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade

  • A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

    S. Jagannath;B. Barlogie;J. Berenson;D. Siegel

  • Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents

    Bart Barlogie;Lon Smith;Raymond Alexanian

  • Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma

    Donna M Weber;Kim Rankin;Maria Gavino;Kay Delasalle

  • Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.

    Raymond Alexanian;Arthur Haut;Asad U. Khan;Montague Lane

  • Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

    Paul G. Richardson;Hannah Briemberg;Sundar Jagannath;Patrick Y. Wen

  • Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

    Jordan U. Gutterman;George R. Blumenschein;Raymond Alexanian;Hwee-Yong Yap

  • The Treatment of Multiple Myeloma

    Raymond Alexanian;Meletios Dimopoulos

  • Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.

    Jordan U. Gutterman;Seymour Fine;Jorge Quesada;Sandra J. Horning

  • Primary dexamethasone treatment of multiple myeloma.

    Raymond Alexanian;Meletios A. Dimopoulos;Kay Delasalle;Bart Barlogie

  • Solitary plasmacytoma of bone and asymptomatic multiple myeloma.

    Meletios A. Dimopoulos;Lia A. Moulopoulos;Lia A. Moulopoulos;Lia A. Moulopoulos;Alice Maniatis;Alice Maniatis;Alice Maniatis;Raymond Alexanian;Raymond Alexanian;Raymond Alexanian

  • High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.

    Bart Barlogie;Roy Hall;Axel Zander;Karel Dicke

  • Plasma cell myeloma--new biological insights and advances in therapy.

    Bart Barlogie;Joshua Epstein;Peter Selvanayagam;Raymond Alexanian

  • VAD-based regimens as primary treatment for multiple myeloma.

    Raymond Alexanian;Bart Barlogie;Susan Tucker

  • Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

    Robert A. Kyle;Steven P. Treon;Raymond Alexanian;Bart Barlogie

  • Nuclear factor–κB and STAT3 are constitutively active in CD138+cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis

    Alok C. Bharti;Shishir Shishodia;James M. Reuben;Donna Weber

  • Renal failure in multiple myeloma. Pathogenesis and prognostic implications.

    Raymond Alexanian;Bart Barlogie;Dennis Dixon

  • Waldenstrom's macroglobulinemia

    MA Dimopoulos;R Alexanian

  • High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma

    Bail Barlogie;Raymond Alexanian;Karel A. Dicke;Gunar Zagars

Frequent Co-Authors

Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center
Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Bart Barlogie
Bart Barlogie Mount Sinai Hospital
Jordan U. Gutterman
Jordan U. Gutterman The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Sundar Jagannath
Sundar Jagannath Icahn School of Medicine at Mount Sinai
Robert A. Kyle
Robert A. Kyle Mayo Clinic
Kenneth C. Anderson
Kenneth C. Anderson Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are several related degree options and career pathways that you can also explore online. These programs offer flexibility for working professionals, career changers, or those wishing to expand their healthcare expertise.

For those interested in the business and leadership side of healthcare, a healthcare administration degree can open doors to management roles in hospitals, clinics, and public health organizations. Licensed nurses aiming to advance clinical and leadership skills might consider adn to msn bridge programs for a streamlined educational path from associate to master’s level credentials.

Nutrition is another essential aspect of healthcare, and a nutritionist online degree prepares students for careers in dietetics, wellness coaching, and community health. Those seeking executive positions may be interested in cahme accredited online mha programs, which are recognized for their rigorous standards and value in the healthcare industry.

Exploring these related degrees can help you find the right fit for your career goals in the rapidly evolving healthcare sector.

Best Scientists Citing Raymond Alexanian

Trending Scientists

Recently Published Articles